KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Emergent BioSolutions (EBS) Income from Continuing Operations (2016 - 2026)

Emergent BioSolutions has reported Income from Continuing Operations over the past 16 years, most recently at 6800000.0 for Q1 2026.

  • For Q1 2026, Income from Continuing Operations fell 90.0% year-over-year to 6800000.0; the TTM value through Mar 2026 reached 8600000.0, up 93.47%, while the annual FY2025 figure was 52600000.0, 127.6% up from the prior year.
  • Income from Continuing Operations for Q1 2026 was 6800000.0 at Emergent BioSolutions, up from 54600000.0 in the prior quarter.
  • Over five years, Income from Continuing Operations peaked at 114800000.0 in Q3 2024 and troughed at 283100000.0 in Q2 2024.
  • A 5-year average of 65052941.18 and a median of 49500000.0 in 2023 define the central range for Income from Continuing Operations.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 4932.43% in 2023 and later skyrocketed 655.56% in 2025.
  • Year by year, Income from Continuing Operations stood at 67000000.0 in 2022, then rose by 26.12% to 49500000.0 in 2023, then soared by 36.77% to 31300000.0 in 2024, then crashed by 74.44% to 54600000.0 in 2025, then surged by 112.45% to 6800000.0 in 2026.
  • Business Quant data shows Income from Continuing Operations for EBS at 6800000.0 in Q1 2026, 54600000.0 in Q4 2025, and 51200000.0 in Q3 2025.